carDIo-ttranSSfOrm nucLEar Imaging Study

Related Clinical Trial
Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy Early Detection of Neuropathy in ATTRv carDIo-ttranSSfOrm nucLEar Imaging Study SGLT2 Inhibitors in ATTR Analysis of the Instestinal Microbiome of Patients With Transthyretin Amyloidosis Amyloidosis TTR Flow Reserve Evaluation Autonomic Evaluation of Patients With Hereditary Amyloidotic Cardiomyopathy: Hereditary Amyloidotic Heart Disease Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study) Exercise Effect on Transthyretin Stability Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis ION-682884 in Patients With TTR Amyloid Cardiomyopathy The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Bern Cardiac Amyloidosis REgistry (B-CARE) Unmasking the Prevalence of AC in an Unselected Echocardiographic Population Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy Global Prevalence of ATTR-CM in Participants With HFpEF Penn Biobank Return of Research Results Program Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan) Open-Label Study of AG10 in Patients With Cardiomyopathy Screening for Systemic Amyloidosis Via the Ligamentum Flavum DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers Cardiac Amyloidosis Screening at Trigger Finger Release Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP) Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis Among Patients Undergoing Carpal Tunnel Release Surgery – A Prospective Study The Effect of Diflunisal on Familial Amyloidosis Epidemiological Analysis for the Hereditary Transthytetin-related Amyloidosis (hATTR) Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study Transthyretin-Associated Amyloidosis Outcome Survey (THAOS) Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Study of SOM0226 in Familial Amyloid Polyneuropathy Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology

Brief Title

carDIo-ttranSSfOrm nucLEar Imaging Study

Official Title

carDIo-ttranSSfOrm nucLEar Imaging Study

Brief Summary

      The investigators will evaluate the change in myocardial uptake of 99m-technetium
      pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in
      the CARDIO-TTRansform clinical trial (NCT04136171).

Detailed Description

      This is a multicenter trial of 80 subjects enrolled in the CARDIO-TTRansform randomized
      clinical trial (NCT04136171) who will undergo baseline and follow up Tc-99m PYP to assess for
      the change in myocardial uptake of the tracer.

Study Phase

Phase 3

Study Type


Primary Outcome

Primary outcome

Secondary Outcome

 Secondary outcome




99m-technetium pyrophosphate scintigraphy

Study Arms / Comparison Groups

 Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform
Description:  Patients will undergo serial Tc-99m PYP imaging at baseline, week 61 and end of trial


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Diagnostic Test

Estimated Enrollment


Start Date

January 19, 2022

Completion Date

December 30, 2026

Primary Completion Date

December 30, 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Patients who were screened and eligible to be enrolled or have been already enrolled
             in the CARDIO-TTRansform randomized clinical trial (NCT04136171) and have a baseline
             99m-technetium pyrophosphate planar and SPECT imaging done within 12 months prior to
             screening for CARDIO-TTRansform.

          -  Patients have to meet the inclusion and exclusion criteria of CARDIO-TTRansform trial
             to be enrolled.

          -  Patient willing to consent for the study and undergo the study procedures.

        Exclusion Criteria:

          -  None




60 Years - 90 Years

Accepts Healthy Volunteers



Ahmad Masri, MD MS, 503-494-8582, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Oregon Health and Science University


 Ionis Pharmaceuticals, Inc.

Study Sponsor

Ahmad Masri, MD MS, Study Chair, Oregon Health and Science University

Verification Date

February 2022